posted on 2022-02-23, 06:56authored byJames E. Frampton
The Entrectinib in NTRK+ Solid
Tumours and ROS1+ NSCLC Adis Drug Evaluation
video abstract, script and image slide deck provide a brief overview of the
mechanism of action of entrectinib in NTRK+
solid tumours and ROS1+ NSCLC,
the administration regimen and the key efficacy and tolerability outcomes from
clinical trials.
The video abstract, script and
slide deck, which have been peer reviewed and were uploaded to Figshare after
the Entrectinib in NTRK+ Solid
Tumours and ROS1+ NSCLC Adis Drug Evaluation
was published, are sponsored by F. Hoffmann-La Roche.